media – Page 79 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

SINOPHARM’s first batch of antibody products officially shipped! Will bring new treatment options for lymphoma patients

On July 22, the first batch of SINOPHARM’s first antibody drug Sanglijian® (rituximab injection) was officially shipped, marking the company’s antibody drug formally entered a new journey of commercialization. Patient’s Gospel, First-line Targeted Drugs for Hematologic Tumors Lymphoma is a malignant tumor originated from lymphohematopoietic system, which belongs to immune system diseases. Malignant lymphoma is mostly non-Hodgkin’s lymphoma, accounting for about 80%-90% of all lymphoma cases. According to the data released by the National Cancer Center, the current incidence rate of lymphoma in China is about 6/100,000, with nearly 100,000 new cases every year, causing serious harm to patients’ lives, health and quality of life. Sanglijian® (rituximab injection) is mainly used for the treatment of non-Hodgkin’s lymphoma (follicular non-Hodgkin’s lymphoma, CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma), chronic lymphoma cell leukemia (CLL) indications, and it is the first-line targeted drug of hematological tumors. According to the research, SUNLIFE® combined with CHOP ...
- Source: drugdu
- 95
- July 24, 2024
Hengrui Pharmaceuticals’ Innovative Drug Dalsili, HRS-1358 Combination for Breast Cancer Approved for Clinical Trial

Recently, Hengrui Pharmaceuticals and its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, approving the company’s novel and highly selective CDK4/6 inhibitor, dalsiril hydroxyethanesulfonate tablets, combined with HRS-1358 tablets to carry out a clinical trial for breast cancer. Breast cancer is the number one malignant tumor affecting women worldwide. According to the Global Cancer Epidemiology Report 2024, the incidence and mortality rates of breast cancer rank first among female malignant tumors, with approximately 2.31 million new cases of breast cancer and 670,000 deaths globally each year, ranking first in terms of incidence and mortality rates of female malignant tumors [1]. In recent years, the incidence and mortality rates of breast cancer have shown a continuous upward trend in China, and it ranks fourth among the causes of cancer death. HRS-1358 is a novel, highly efficient and ...
- Source: drugdu
- 83
- July 24, 2024
Glasgow scientists develop first bone marrow model to support human stem cells

Scientists from the University of Glasgow have developed the first bioengineered bone marrow model that supports human stem cells, which are crucial for bone marrow transplants and in vitro study work. Published in Nature Communications, the new model replicates the key aspects of the human bone marrow microenvironment to support rare long-term haematopoietic stem cells (LT-HSCs). Estimated to cause more than 300,000 deaths worldwide every year, leukaemia is a type of blood cancer that affects the white blood cells in the bone marrow, the spongy tissue found inside some bones, where the body makes blood cells. LT-HSCs are a type of cell that can replenish the blood cells after treatment for blood cancers, such as leukaemia. However, due to culturing challenges, researchers often rely on non-human animal models to test drugs that can have effects on blood cell production and target blood diseases. “Currently used animal models are poor predictors ...
- Source: drugdu
- 74
- July 24, 2024
+ Study finds pain gene affects success of chronic pain medicine in women

A study led by the University of Edinburgh in collaboration with the University of Oxford has found that a pain gene carried by women with chronic pelvic pain makes them more likely to respond well to Pfizer’s painkilling drug, Neurontin (gabapentin). Published in the journal iScience, the study found that women carrying a naturally occurring variation of the gene called Neuregulin 3 in their DNA were more likely to experience relief after taking Neurontin. Chronic pelvic pain is a persistent, disabling pain that affects around one in four women globally. Often prescribed for chronic pain, Neurontin is designed to target the central nervous system to reduce the heightened pain sensitivity that affects people living with long-standing conditions. After studying the genetic make-up of 71 women living with chronic pelvic pain who had received Neurontin, researchers found that 29 women responded to the medication, while 42 saw no improvement. The team ...
- Source: drugdu
- 85
- July 24, 2024
Exhaled-Breath Test Shows Promise for Detection of Lung Cancer

Researchers are advancing the development of an exhaled-breath test to detect lung diseases, including lung cancer. Two pivotal studies published in the Journal of Extracellular Vesicles detail their success in isolating and analyzing lung biomarkers from human breath and utilizing animal models to further explore and possibly identify crucial markers for the early and non-invasive detection of metastatic lung tumors. While substantial efforts are needed to identify a spectrum of biomarkers and validate their clinical relevance for human patients, these publications provide a scientific framework for continued research. The research by scientists at Hackensack Meridian Health (Edison, NJ, USA) focuses on capturing and characterizing extracellular vesicles (EVs), nanoparticles released by cells into fluids like blood and serum. Cancer cells release these particles abundantly, making them prime targets for early disease detection. The researchers have initiated biomarker discovery projects for several cancers, including lung, prostate, cervical, and bladder cancers, using liquid ...
- Source: drugdu
- 94
- July 23, 2024
World’s First Rapid Diagnostic Test Detects Stroke within Minutes at POC

Each year, more than 20 million people worldwide suffer from strokes. Large vessel occlusions (LVO) constitute 30% of these cases but are behind 95% of the resulting disabilities and fatalities. The likelihood of recovery improves significantly if a procedure known as ‘thrombectomy’ is performed immediately after the onset of symptoms. However, speeding up this treatment is complicated because it’s difficult to identify LVO strokes outside hospital settings; symptoms can mimic other medical issues. Strokes can also result from blockages in smaller vessels or vessel ruptures, neither of which are suitable for thrombectomy. Ideally, LVO strokes need to be diagnosed quickly and before the patient arrives at the hospital to speed up the initiation of thrombectomy. Currently, there is no sufficiently accurate diagnostic tool for this purpose. Now, a groundbreaking diagnostic test can identify an LVO stroke within 15 minutes, expediting patient transfer to specialized care and saving more than 1 ...
- Source: drugdu
- 132
- July 23, 2024
Artiva’s IPO Reels In $167M to Bring NK Cell Therapy to Autoimmune Diseases

Lupus is the lead autoimmune indication for Artiva Biotherapeutics, which has an early-stage clinical trial underway. Artiva’s allogeneic cell therapies are based on natural killer cells. By Frank VinluanCell therapy first reached patients as treatments for cancer. Artiva Biotherapeutics is part of a growing group of companies working to bring cell therapy to autoimmune disease, and its IPO has raised $167 million for clinical trial plans. Artiva priced the IPO at $12 per share, which was below the $14 to $16 per share price range the biotech set in preliminary terms last week. However, it boosted the deal size by increasing the number of shares in the offering. The 8.7 million shares it initially planned to offer would have raised $130.5 million at the proposed pricing midpoint. The company was able to raise more by selling 13.92 million shares. The shares of San Diego-based Artiva shares debuted on the Nasdaq ...
- Source: drugdu
- 75
- July 23, 2024
Is There a Correlation Between Medical Debt and Delayed Mental Health Care in the United States?

By Don Tracy, Associate Editor JAMA study aims to determine whether financial barriers impact access to mental health services.In the United States, a number of low-income adults struggle to gain access to appropriate mental health care. Despite efforts such as new legislations aimed at extending both private and public insurance through the Affordable Care Act (ACA), financial barriers are still an issue. In a study published in JAMA Psychiatry, researchers aimed to discover whether there was an association between medical debt and delayed or forgone mental health care among adults in the United States. The study included data from the 2022 National Health Interview Survey, which measured responses from 27,651 adults with current or lifetime diagnoses of depression or anxiety. Additionally, Asian, Black, and Hispanic households were oversampled to improve precision of estimates for these groups. To provide accurate results, mental health status was assessed for depression and anxiety, measured ...
- Source: drugdu
- 99
- July 23, 2024
Psilocybin and undisclosed ingredients found in popular mushroom gummies

Mushroom gummies being sold to promote brain function may contain the illegal hallucinogen psylocibin and other harmful ingredients not listed on the label, UVA Health experts are warning after five people – including a 3-year-old child – were sickened. A spate of cases seen in UVA Health Medical Center’s emergency department between September and June prompted poison experts with UVA’s Blue Ridge Poison Center to test five different brands of the products sold in Central Virginia gas stations and smoke shops. Of those, three contained psilocybin or psilocin, substances classified as “Schedule I” drugs by the U.S. Food and Drug Administration, meaning they have no medical use and high potential for abuse. Psilocybin and psilocin are illegal at both the federal and state level. All the products tested claimed to contain the Amanita muscaria mushroom, which is legal, or a proprietary mushroom blend. But none disclosed the inclusion of psilocybin ...
- Source: drugdu
- 71
- July 22, 2024
Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders. GLP-1 is a hormone released from the gut after eating that enhances glucose-dependent insulin secretion. Pharmacological GLP-1 receptor (GLP-1R) activation reduces glucagon secretion and slows gastric emptying, making it an effective treatment for type 2 diabetes. Later studies found that GLP-1 administration also inhibited food intake through GLP-1R activation in the brain, leading to their use in treating obesity. Recently, research has demonstrated that GLP-1 drugs produce additional health benefits beyond glucose and weight control, including reduced heart and kidney diseases. Here, Drucker discusses the potential mechanisms underlying these benefits, such as reducing systemic inflammation, and their implications for future clinical applications and drug development. According to Drucker et al., GLP-1 drugs have shown promise ...
- Source: drugdu
- 93
- July 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.